Pf-06823859 — Competitive Intelligence Brief

Pf-06823859 (pf-06823859) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal Antibody. Area: Oncology.

marketed Monoclonal Antibody PD-1/PD-L1 Oncology

Target snapshot

Pf-06823859 (pf-06823859) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pf-06823859 TARGET	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
MAZ-101association	MAZ-101association	EMS	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
Pembrolizumab/Vibostolimab Co-Formulation	Pembrolizumab/Vibostolimab Co-Formulation	Merck Sharp & Dohme LLC	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
SYS6010	SYS6010	Fujian Cancer Hospital	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
TQB3616 capsule	TQB3616 capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal Antibody class)

1. Pfizer · 3 drugs in this class
2. National Medical Research Center for Children's Health, Russian Federation · 1 drug in this class
3. Pfizer Inc · 1 drug in this class